CCKBR and familial pancreatic carcinoma: Since NP delivery platforms have demonstrated safety and ability to scale-up for clinical translation, use of our NP that selectively targets the CCK-B receptor further increases optimism that muKRAS can be targeted and survival from pancreatic cancer improved.